Daniela Miliziano, Daniela Miliziano, Medical Oncology Fellow at Gustave Roussy, shared a post on X:
“Great experience at AACR presenting our work from the RET-MAP registry in RET+ NSCLC.
Under SRI (any line):
- TP53 mut vs wt: mPFS 8.9 vs 19.2 mo
- KIF5B-RET vs CCDC6-RET: mPFS 13.4 vs 60.2 mo.
Thanks to Mihaela Aldea for the support!”

Zoldonrasib Shows Early Strength in Previously Treated KRAS G12D NSCLC
